Thermo Fisher Makes Final Push For ‘Universal’ Lung-Cancer Companion Dx
The Oncomine Universal Dx looks in parallel for mutations on four genes associated with non-small cell lung cancer to help physicians pick between different drug options. Thermo Fisher has submitted its final PMA module to FDA.
You may also be interested in...
A top reviewer in US FDA's in vitro diagnostics office offers tips to next-generation sequencing test sponsors to avoid common submission shortcomings in this interview with Medtech Insight. According to FDA's Hisani Madison, sponsors frequently fall short in providing a refined intended-use statement.
The pivotal data presented at ASCO showed a 76% response rate for the TRK inhibitor in patients with TRK fusion abnormalities, but there's still a lot left to prove about the tissue-agnostic model of drug development.
The FoundationOne assay has been accepted into FDA's Expedited Access Pathway and the FDA/CMS Parallel Review program in an effort to advance what would be the first assay approved as a companion diagnostic for a range of tumor targets and drugs at once.